A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
Public ClinicalTrials.gov record NCT05972174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).
Study identification
- NCT ID
- NCT05972174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 1,504 participants
Conditions and interventions
Conditions
Interventions
- mRNA-1018 for H5N8 Biological
- mRNA-1018 for H7N9 Biological
- mRNA-1018 for H5 Only Biological
- mRNA-1018 for H7 Only Biological
- mRNA-1018 for H5 Only-CG Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2023
- Primary completion
- Jul 15, 2024
- Completion
- Jul 15, 2024
- Last update posted
- Jul 15, 2025
2023 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CenExel RCA | Hollywood | Florida | 33024 | — |
| Velocity Clinical Research | Savannah | Georgia | 31406 | — |
| Johnson County Clin-Trials | Lenexa | Kansas | 66219 | — |
| DM Clinical Research | Southfield | Michigan | 48076 | — |
| Velocity Clinical Research | Lincoln | Nebraska | 68510 | — |
| Velocity Clinical Research Providence | East Greenwich | Rhode Island | 02818 | — |
| DM Clinical Research | Sugar Land | Texas | 77478 | — |
| DM Clinical Research | Tomball | Texas | 77375 | — |
| J. Lewis Research, Inc/Jordan River Family Medicine | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
Recently updated Influenza trials
Other public records listing Influenza. Sorted by last update posted; newest first. Not a recommendation.
- NCT07496450: A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults Active, not recruiting
- NCT07703514: Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates Not yet recruiting
- NCT06029933: Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years Recruiting
- NCT07215858: BPL-1357 Against H1N1 Influenza Virus Challenge Recruiting
- NCT04712539: Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients Recruiting
- NCT07149428: Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI) Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05972174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2025 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05972174 live on ClinicalTrials.gov.